Edition:
India

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

12.13USD
23 Feb 2018
Change (% chg)

$0.17 (+1.42%)
Prev Close
$11.96
Open
$12.05
Day's High
$12.21
Day's Low
$11.83
Volume
32,828
Avg. Vol
47,709
52-wk High
$19.50
52-wk Low
$10.26

Chart for

About

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and... (more)

Overall

Beta: -0.09
Market Cap(Mil.): $427.87
Shares Outstanding(Mil.): 25.51
Dividend: --
Yield (%): --

Financials

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage:

02 Feb 2018

BRIEF-Oxford Immunotec Announces Preliminary Revenue For Q4

* FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S

08 Jan 2018

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

16 Dec 2017

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

22 Nov 2017

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

31 Oct 2017

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

27 Sep 2017

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - ‍on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies ​

07 Sep 2017

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

30 Aug 2017

Competitors

  Price Chg
Thermo Fisher Scientific Inc. (TMO.N) $211.71 +2.58
Bruker Corporation (BRKR.OQ) $31.79 +0.56
STERIS Corp (STE.N) $91.78 +1.14

Earnings vs. Estimates